115 related articles for article (PubMed ID: 19197721)
41. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
42. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan.
DeMonaco NA; Jacobs SA
Clin Nucl Med; 2007 Dec; 32(12):933-4. PubMed ID: 18030044
[TBL] [Abstract][Full Text] [Related]
43. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count.
Hopfinger G; Plessl A; Grisold W; Klimpfinger M; Höftberger R; Bernt R; Möstl M; Waldner R; Pittermann-Höcker E
Leuk Lymphoma; 2008 Dec; 49(12):2367-9. PubMed ID: 19052987
[No Abstract] [Full Text] [Related]
44. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
45. Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.
Li ZM; Ghielmini M; Moccia AA
Expert Rev Anticancer Ther; 2013 Mar; 13(3):313-25. PubMed ID: 23477518
[TBL] [Abstract][Full Text] [Related]
46. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
[TBL] [Abstract][Full Text] [Related]
47. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
48. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
[TBL] [Abstract][Full Text] [Related]
49. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
Turturro F
Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
Zhao F; Cheng LL; Zheng Z; Zhang MC; Cheng S; Xu PP; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):513-517. PubMed ID: 35968596
[No Abstract] [Full Text] [Related]
51. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study.
Johnston A; Bouafia-Sauvy F; Broussais-Guillaumot F; Michallet AS; Traullé C; Salles G; Coiffier B
Leuk Lymphoma; 2010 Mar; 51(3):399-405. PubMed ID: 20038227
[TBL] [Abstract][Full Text] [Related]
52. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab.
Buckstein RJ; Rimrie K; Pennell N; Spaner D; Hewitt K; Berinstein NL
Leuk Lymphoma; 2001 Apr; 41(3-4):451-5. PubMed ID: 11378562
[TBL] [Abstract][Full Text] [Related]
53. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
Cohen Y; Libster D; Da'as N; Amir G; Polliack A
Hematol J; 2003; 4(2):151-3. PubMed ID: 12750735
[TBL] [Abstract][Full Text] [Related]
54. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma.
Yang SH; Kuo SH
Ann Hematol; 2008 Apr; 87(4):325-7. PubMed ID: 17932671
[No Abstract] [Full Text] [Related]
55. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
[TBL] [Abstract][Full Text] [Related]
56. Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma.
Minson A; Dickinson M
Leuk Lymphoma; 2021 Sep; 62(9):2047-2049. PubMed ID: 34105426
[No Abstract] [Full Text] [Related]
57. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
58. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
Tobinai K; Ogura M; Kobayashi Y; Uchida T; Watanabe T; Oyama T; Maruyama D; Suzuki T; Mori M; Kasai M; Cronier D; Wooldridge JE; Koshiji M
Cancer Sci; 2011 Feb; 102(2):432-8. PubMed ID: 21205069
[TBL] [Abstract][Full Text] [Related]
59. Rituximab for follicular non-Hodgkin lymphoma.
Gajraj E; Chung H; Longson C; Stevens A
Lancet Oncol; 2008 Apr; 9(4):320-1. PubMed ID: 18405852
[No Abstract] [Full Text] [Related]
60. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
Jensen M; Elter T; Engert A; Reiser M
Onkologie; 2006 Mar; 29(3):90-2. PubMed ID: 16514269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
